Skip to main content

BNTX · BioNTech SE

Track BNTX — free
$86.26 +0.66 (+0.77%)
Market Cap
$21.22B
Shares
247.93M
Volume · Nov 16 503.44K Avg daily vol (3M) 1.23M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$85.60 Open$85.12 Day$84.23–86.00 52W close$83.89–119.34 Avg vol 30d1.1M Short int2.2M · 0.9% of shares · 2.2d Short vol27% Last earningsNov 3, 2026 DataJan 2020–Nov 2026

Up next

Mar 2, 2027 Scheduled · in 15 wks

Latest documents

2026
Nov 10
Current report 6-K
BioNTech to buy FDA priority review voucher for $205 million

On November 10, 2026, BioNTech SE agreed to acquire a US FDA Priority Review Voucher from Scholar Rock, Inc. for $205 million, intending to use it for a future late-stage oncology filing; closing requires customary conditions, including HSR clearance.

3 source passages
MAINZ, Germany, November 10, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that it has entered into an agreement to acquire a US Food and Drug Administration (“FDA”) Priority Review Voucher (“PRV”) from Scholar Rock, Inc. (Nasdaq: SRRK, “Scholar Rock”) for a total cash consideration of $205 million. BioNTech intends to use the PRV to support a future filing of an asset in its late-stage oncology pipeline. The transaction is subject to customary closing conditions, including clearance under the Hart-Scott Rodino (“HSR”) Antitrust Improvements Act. Open the document at this passage
Nov 3
Earnings call
Gotistobard nearly doubled median overall survival

BioNTech said Gotistobard achieved median overall survival of 18.5 months versus 10 months with docetaxel in a global phase 3 lung-cancer trial, reducing death risk by 44%; the first pivotal interim analysis is expected before year end.

4 source passages
BioNTech is well positioned for the next phase of growth. We are advancing Gotistobard through the pivotal stage of a global phase 3 trial in patients with metastatic squamous non-small cell lung cancer who progressed following platinum-based chemotherapy and checkpoint inhibitor treatment. Median overall survival was 18.5 months with gotistobard versus 10 months with docetaxel with a hazard ratio of 0.56. Gotistobard reduced the risk of death by 44% compared with chemotherapy. We anticipate an interim analysis before year end. Open the document at this passage
Nov 3
Current report 6-K
Net profit returns as nine-month loss widens

BioNTech SE reported revenue of 1,289.2 million euros for the three months ended September 30, 2026 and net profit of 184.5 million euros, while nine-month revenue was 1,512.9 million euros and net loss was 1,168.2 million euros.

Read from the first part of this long document
3 source passages
Three months ended September 30, | Nine months ended September 30, | 2026 | 2025 | (in millions €, except per share data) Revenues | 3 | 1,289.2 | 1,518.9 | 1,512.9 | 1,962.5 Net profit / (loss) | | 184.5 | (28.7) | (1,168.2) | (831.1) Open the document at this passage
Nov 3
Current report 6-K
Revenue guidance raised as Q3 profit swings positive

BioNTech SE reported third-quarter revenue of €1,289.2 million and net profit of €184.5 million, raised full-year revenue guidance to €1,700 – €1,900 million, and reported €16.2 billion in cash, cash equivalents and security investments.

Read from the first part of this long document
5 source passages
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today reported financial results for the three and nine months ended September 30, 2026 and provided an update on its corporate progress. Third quarter 2026 revenues of €1,289.2 million1, adjusted2 R&D expenses of €578.5 million (IFRS R&D expenses of €748.1 million), and adjusted SG&A3 expenses of €178.5 million Net profit was €184.5 million for the third quarter of 2026, compared to a net loss of €28.7 million. Raised full-year 2026 revenue guidance midpoint and updated range to €1.7–1.9 billion, and maintained strong financial position with cash, cash equivalents and security investments of €16.2 billion4 Revenues | €1,700 – €1,900 million | €1,600 – €1,900 million Open the document at this passage
Oct 26
Current report 6-K
Current report

BioNTech SE and Bristol Myers Squibb Company reported first Phase 2 ROSETTA Lung-107 data: pumitamig plus docetaxel achieved a 36.7% confirmed objective response rate and 6.9-month median progression-free survival.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+4.3%
Year over year
Operating margin
-49.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.7%
Year over year · more shares
Price change (1Y)
-17.6%
Trailing year
Short interest
0.9%
Latest settlement · 2.2 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Limited Quant / Vol High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −11%
below
Price vs 50-day avg −8%
below
RSI (14) 40
neutral
MACD trend Positive
52-week position 5%
near low
Momentum
relative strength
Very Weak
1-month return −2%
trailing
6-month return −7%
trailing
YTD return −10%
this year
Relative strength −8%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $93 › 200d $96 — 200d above 50d
Institutional flow Accumulating
252 of 288 funds reported for Sep 30 · net +349.9K sh shares · +34 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.91% of shares out · ▼ -1.2% MoM · 2.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
288 holders — mid 3-yr range
Squeeze score 41
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
High
Volatility 47%
annualized · 1-yr
Max drawdown −30%
past year
ATR 3.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed May 5, 2026
full year 2026
Adjusted R&D expenses Non-GAAP $2.2B – $2.5B
Adjusted S&A expenses Non-GAAP $700M – $800M
over the coming 12 months
Share report chase program of American depository shares up to $1B
once the measures are fully implemented
Recurring annual savings $500M
Prior guidance period ended · from the Earnings Call filed May 5, 2026
BMS collaboration payment · third quarter of 2026 $613M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−11% Bearish
Price vs 50-day avg
−8% Bearish
RSI (14)
40 Neutral
MACD trend
Positive Bullish
52-week position
5% Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $93 › 200d $96 — 200d above 50d
Institutional flow Accumulating
252 of 288 funds reported for Sep 30 · net +349.9K sh shares · +34 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.91% of shares out · ▼ -1.2% MoM · 2.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
288 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $84 Now $86 · 5% Range high $119
vs 200-day avg -11% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BNTX
BioNTech SE
this stock
$21.22B -10.1% — — 0.9%
VRTX
Vertex Pharmaceuticals Inc
$136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
$87.65B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
$66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
299
% held
19.1%
Reported
252 of 288
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
142
View
Short & Settlement
Short Interest Falling
Shares short
2.2M
Days to cover
2.2d
Change
-26.6K sh
View
Short Volume
Short vol %
27%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
63
Value
$5.6K
As of
Oct 20, 2026
View
Off-Exchange
Off-exchange %
37.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Valerie Hoyle
Amount
$1.0K–$15.0K
Traded
Aug 7, 2025
View
Financials
Buybacks
Authorized
$1.0B
Remaining
$536.7M
Spent Remaining
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 10, 2026
This year
36

On November 10, 2026, BioNTech SE agreed to acquire a US FDA Priority Review Voucher from Scholar Rock, Inc. for $205 million, intending to use it for a future late-stage oncology filing; closing requires customary conditions, including HSR clearance.

View
Proposed Sales
Value
$89.1M
Shares
858.2K
Filed
Sep 3, 2026
View
Exempt Offerings
Offering
$150.0M
Filed
Apr 14, 2022
View
Earnings & Events
Webcasts Upcoming
Next webcast
Mar 2, 2027
Last webcast
Nov 3, 2026
View
Investor Relations
Latest news
BioNTech to Acquire US FDA Priori…
Published
Nov 10, 2026
Upcoming events
5
View

Performance

5D 20D 120D MTD YTD
BNTX -2.2% -2.4% -7.2% -2.9% -10.1%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -4.8% -1.3% -7.7% -2.7% -20.7%

Capital returns

Latest dividend
$2.111 / share · ex Jun 2, 2022
Paid (TTM)
$0.00 / share · 0 payouts
Dividend yield (TTM, derived)
— · no payout in the trailing year
Full dividend history
Buyback program · as of Sep 30, 2026
Authorized
$1.00B
Spent (derived)
$463.30M
Remaining
$536.70M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1776985 CUSIP 09075V102 13F (30d) 239 filings 212 filers Visit website Investor relations